The abstract is read at the publisher; the summary is JClub's.
PMOS affected 17.1% (95% CI 15.9–18.3) of 3,645 pregnant women in an international multicenter cohort, and was linked to higher odds of early GDM.
- Why it matters: The study addresses whether polyendocrine metabolic ovarian syndrome is associated with maternal and neonatal complications, and whether BMI or ethnicity modifies these risks.
- What they did: In a prospective nested cohort within a randomized trial for gestational diabetes mellitus treatment, outcomes were compared by PMOS status and adjusted for age, baseline BMI, ethnicity, parity, smoking, and education.
- The result: After adjustment, PMOS predicted early GDM (aOR 1.37, 95% CI 1.10–1.72), a composite adverse neonatal outcome (aOR 1.28, 95% CI 1.04–1.58), and NICU/special care admission (aOR 1.32, 95% CI 1.05–1.65), while being associated with shorter gestational age (-1.60 days) and birth length (-0.33 cm).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.